Inogen
- Home ›
- US ›
- Healthcare
Inogen, Inc., a medical technology company, primarily develops, manufactures, and markets portable oxygen concentrators for patients, physicians and other clinicians, and third-party payors in the United States and internationally. The last earnings update was 22 days ago. More info.
Add to Portfolio Compare Print
- Inogen has significant price volatility in the past 3 months.
INGN Share Price and Events
7 Day Returns
1 Year Returns
INGN Shareholder Return
| 7 Day | 30 Day | 90 Day | 1 Year | 3 Year | 5 Year | |
|---|---|---|---|---|---|---|
| Inogen (INGN) | -1.4% | -32.3% | -16.8% | -23.4% | 134% | 474.1% |
| US Medical Equipment | 1.1% | 2.6% | 13.6% | 20.3% | 70.3% | 98.3% |
| US Market | 1.6% | 2.1% | 12.8% | 3.2% | 38.6% | 43.6% |
1 Year Return vs Industry and Market
- INGN underperformed the Medical Equipment industry which returned 20.3% over the past year.
- INGN underperformed the Market in United States of America which returned 3.2% over the past year.
Value
Is Inogen undervalued based on future cash flows and its price relative to the stock market?
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current
share
price of
Inogen
to its discounted cash flow analysis.value.The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Below are the data sources, inputs and calculation used to determine the intrinsic value for Inogen.
| Data Point | Source | Value |
|---|---|---|
| Valuation Model | 2 Stage Free Cash Flow to Equity | |
| Levered Free Cash Flow | Average of 7 Analyst Estimates (S&P Global) | See below |
| Discount Rate (Cost of Equity) | See below | 8.4% |
| Perpetual Growth Rate | 10-Year US Government Bond Rate | 2.7% |
An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.
| Data Point | Calculation/ Source | Result |
|---|---|---|
| Risk-Free Rate | 10-Year US Govt Bond Rate | 2.7% |
| Equity Risk Premium | S&P Global | 6% |
| Medical Equipment Unlevered Beta | Simply Wall St/ S&P Global | 0.93 |
| Re-levered Beta | = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.931 (1 + (1- 21%) (0%)) |
0.954 |
| Levered Beta | Levered Beta limited to 0.8 to 2.0 (practical range for a stable firm) |
0.95 |
| Discount Rate/ Cost of Equity |
= Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 2.73% + (0.954 * 5.96%) |
8.41% |
Discounted Cash Flow Calculation for NasdaqGS:INGN using 2 Stage Free Cash Flow to Equity Model
The calculations below outline how an intrinsic value for Inogen is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.
| Levered FCF (USD, Millions) | Source |
Present Value Discounted (@ 8.41%) |
|
|---|---|---|---|
| 2019 | 64.00 | Analyst x1 | 59.03 |
| 2020 | 89.00 | Analyst x1 | 75.72 |
| 2021 | 102.90 | Est @ 15.62% | 80.75 |
| 2022 | 114.99 | Est @ 11.75% | 83.24 |
| 2023 | 125.40 | Est @ 9.05% | 83.73 |
| 2024 | 134.36 | Est @ 7.15% | 82.75 |
| 2025 | 142.19 | Est @ 5.82% | 80.77 |
| 2026 | 149.15 | Est @ 4.9% | 78.15 |
| 2027 | 155.48 | Est @ 4.25% | 75.15 |
| 2028 | 161.38 | Est @ 3.79% | 71.94 |
| Present value of next 10 years cash flows | $771.25 | ||
| Calculation | Result | |
|---|---|---|
| Terminal Value |
= FCF2028
× (1 + g) ÷ (Discount Rate – g)
= $161.38 × (1 + 2.73%) ÷ (8.41% – 2.73%) |
$2,916.79 |
| Present Value of Terminal Value |
= Terminal Value ÷ (1 + r)10
= $2,916.79 ÷ (1 + 8.41%)10 |
$1,300.35 |
| Calculation | Result | |
|---|---|---|
| Total Equity Value |
= Present value of next 10 years cash flows +
Terminal Value
= $771.25 + $1,300.35 |
$2,071.59 |
| Equity Value per Share (USD) |
= Total value / Shares Outstanding
= $2,071.59 / 21.81 |
$94.96 |
| Calculation | Result | |
|---|---|---|
| Value per share (USD) | From above. | $94.96 |
| Current discount | Discount to share price of
$96.11
= -1 x ($96.11 - $94.96) / $94.96 |
-1.2% |
Learn more about our DCF calculations in Simply Wall St’s analysis model .
- The current share price of Inogen is above its future cash flow value.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.The amount the stock market is willing to pay for Inogen's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are
Inogen's earnings available for a low price, and how does
this compare to other companies in the same industry?
| Data Point | Source | Value |
|---|---|---|
| Earnings Per Share * | Company Filings (2018-12-31) in USD | $2.44 |
| NasdaqGS:INGN Share Price ** | NasdaqGS (2019-03-19) in USD | $96.11 |
| United States of America Medical Equipment Industry PE Ratio | Median Figure of 63 Publicly-Listed Medical Equipment Companies | 39.26x |
| United States of America Market PE Ratio | Median Figure of 3,056 Publicly-Listed Companies | 17.77x |
* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.
** Primary Listing of Inogen.
| Calculation | Outcome | |
|---|---|---|
| PE Ratio | = NasdaqGS:INGN Share Price ÷ EPS (both in USD) = 96.11 ÷ 2.44 |
39.42x |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Inogen is overvalued based on earnings compared to the US Medical Equipment industry average.
- Inogen is overvalued based on earnings compared to the United States of America market.
Price based on expected Growth
Does
Inogen's expected growth come at a high price?
| Data Point | Source | Value |
|---|---|---|
| PE Ratio | See PE Ratio Section | 39.42x |
| Net Income Annual Growth Rate | See Future Growth Section. Line of Best Fit* through Consensus Estimate Earnings of 7 Analysts |
11.2%per year |
| United States of America Medical Equipment Industry PEG Ratio | Median Figure of 53 Publicly-Listed Medical Equipment Companies | 2.59x |
| United States of America Market PEG Ratio | Median Figure of 2,107 Publicly-Listed Companies | 1.49x |
*Line of best fit is calculated by linear regression .
| Calculation | Outcome | |
|---|---|---|
| PEG Ratio | = PE Ratio ÷ Net Income Annual Growth Rate = 39.42x ÷ 11.2% |
3.52x |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Inogen is poor value based on expected growth next year.
Price based on value of assets
What value do investors place on
Inogen's
assets?
| Data Point | Source | Value |
|---|---|---|
| Book Value per Share | Company Filings (2018-12-31) in USD | $14.25 |
| NasdaqGS:INGN Share Price * | NasdaqGS (2019-03-19) in USD | $96.11 |
| United States of America Medical Equipment Industry PB Ratio | Median Figure of 187 Publicly-Listed Medical Equipment Companies | 4.44x |
| United States of America Market PB Ratio | Median Figure of 5,154 Publicly-Listed Companies | 1.89x |
| Calculation | Outcome | |
|---|---|---|
| PB Ratio | = NasdaqGS:INGN Share Price ÷ Book Value per Share (both in USD) = 96.11 ÷ 14.25 |
6.74x |
* Primary Listing of Inogen.
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Inogen is overvalued based on assets compared to the US Medical Equipment industry average.
Value checks
We assess Inogen's value by looking at:- Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
- Is the PE ratio less than the market average, and/ or less than the Medical Equipment industry average (and greater than 0)? (2 checks)
- Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
- Is the PB ratio less than the Medical Equipment industry average (and greater than 0)? (1 check) Inogen has a total score of 0/6, see the detailed checks below.
Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.
Full details on the Value part of the Simply Wall St company analysis model.
Future Performance
How is Inogen expected to perform in the next 1 to 3 years based on estimates from 7 analysts?
The future performance of a company is measured in the same way as past
performance, by looking at estimated
growth
and how much profit it is expected to make.Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Earnings growth vs Low Risk Savings
- Inogen's earnings growth is expected to exceed the low risk savings rate of 2.7%.
Growth vs Market Checks
- Inogen's earnings growth is positive but not above the United States of America market average.
- Inogen's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
| Data Point | Source | Value (per year) |
|---|---|---|
| NasdaqGS:INGN Future Earnings Growth Rate | Line of Best Fit* through Consensus Estimate Earnings of 7 Analysts | 11.2% |
| NasdaqGS:INGN Future Revenue Growth Rate | Line of Best Fit* through Consensus Estimate Revenue of 7 Analysts | 14.6% |
| United States of America Medical Equipment Industry Earnings Growth Rate | Market Cap Weighted Average | 20.5% |
| United States of America Medical Equipment Industry Revenue Growth Rate | Market Cap Weighted Average | 7.3% |
| United States of America Market Earnings Growth Rate | Market Cap Weighted Average | 14.3% |
| United States of America Market Revenue Growth Rate | Market Cap Weighted Average | 7.1% |
*Line of best fit is calculated by linear regression .
Industry and Market average data is calculated daily.
Learn more about our growth rate calculations in Simply Wall St’s analysis model.
Analysts growth expectations
| Data Point | Source | Value |
|---|---|---|
| Past Financials | Company Filings (2 months ago) | See Below |
| Future Estimates | Average of up to 7 Analyst Estimates (S&P Global) | See Below |
| Date (Data in USD Millions) | Revenue | Cash Flow | Net Income * | Avg. No. Analysts |
|---|---|---|---|---|
| 2023-12-31 | 787 | 91 | 1 | |
| 2022-12-31 | 680 | 76 | 2 | |
| 2021-12-31 | 591 | 69 | 3 | |
| 2020-12-31 | 517 | 97 | 56 | 7 |
| 2019-12-31 | 435 | 74 | 44 | 7 |
| Date (Data in USD Millions) | Revenue | Cash Flow | Net Income * |
|---|---|---|---|
| 2018-12-31 | 358 | 60 | 52 |
| 2018-09-30 | 335 | 61 | 41 |
| 2018-06-30 | 309 | 64 | 32 |
| 2018-03-31 | 276 | 60 | 26 |
| 2017-12-31 | 249 | 60 | 21 |
| 2017-09-30 | 237 | 53 | 27 |
| 2017-06-30 | 222 | 44 | 25 |
| 2017-03-31 | 212 | 39 | 24 |
| 2016-12-31 | 203 | 31 | 21 |
| 2016-09-30 | 192 | 38 | 19 |
| 2016-06-30 | 179 | 41 | 17 |
| 2016-03-31 | 168 | 37 | 13 |
*GAAP earnings excluding extraordinary items.
Past and Future Earnings per Share
| Data Point | Source | Value |
|---|---|---|
| Past Financials | Company Filings (2 months ago) | See Below |
| Future Estimates | Average of up to 7 Analyst Estimates (S&P Global) | See Below |
All data from Inogen Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.
| Date (Data in USD Millions) | EPS * | EPS High Estimate | EPS Low Estimate | Avg. No. Analysts |
|---|---|---|---|---|
| 2023-12-31 | 3.94 | 3.94 | 3.94 | 1.00 |
| 2022-12-31 | 3.26 | 3.26 | 3.26 | 1.00 |
| 2021-12-31 | 2.90 | 3.17 | 2.71 | 3.00 |
| 2020-12-31 | 2.39 | 2.59 | 2.16 | 5.00 |
| 2019-12-31 | 1.93 | 2.16 | 1.84 | 5.00 |
| Date (Data in USD Millions) | EPS * |
|---|---|
| 2018-12-31 | 2.44 |
| 2018-09-30 | 1.95 |
| 2018-06-30 | 1.53 |
| 2018-03-31 | 1.24 |
| 2017-12-31 | 1.02 |
| 2017-09-30 | 1.31 |
| 2017-06-30 | 1.21 |
| 2017-03-31 | 1.18 |
| 2016-12-31 | 1.02 |
| 2016-09-30 | 0.96 |
| 2016-06-30 | 0.84 |
| 2016-03-31 | 0.64 |
*GAAP earnings excluding extraordinary items.
Future performance checks
We assess Inogen's future performance by looking at:- Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
- Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
- Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
- Is the annual earnings growth rate expected to be above 20%? (1 check)
- Is the annual revenue growth rate expected to be above 20%? (1 check)
- Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Inogen has a total score of 2/6, see the detailed checks below.
Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.
Full details on the Future part of the Simply Wall St company analysis model.
Past Performance
How has Inogen performed over the past 5 years?
The past performance of a company can be measured by how much
growth
it has experienced and how much profit it makes relative to the funds and assets
it has available.
Past earnings growth
Past Earnings growth analysis
- Inogen has delivered over 20% year on year earnings growth in the past 5 years.
- Inogen's 1-year earnings growth exceeds its 5-year average (146.9% vs 46.8%)
- Inogen's earnings growth has exceeded the US Medical Equipment industry average in the past year (146.9% vs 31.2%).
Earnings and Revenue History
All data from Inogen Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.
| Date (Data in USD Millions) | Revenue | Net Income * | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 2018-12-31 | 358.11 | 51.85 | 133.66 | 7.03 |
| 2018-09-30 | 335.37 | 41.19 | 119.73 | 6.66 |
| 2018-06-30 | 309.11 | 32.10 | 106.88 | 5.94 |
| 2018-03-31 | 275.99 | 25.83 | 96.01 | 5.42 |
| 2017-12-31 | 249.44 | 21.00 | 87.26 | 5.31 |
| 2017-09-30 | 236.50 | 26.87 | 81.44 | 5.16 |
| 2017-06-30 | 221.89 | 24.78 | 76.36 | 5.14 |
| 2017-03-31 | 212.34 | 23.93 | 72.36 | 5.25 |
| 2016-12-31 | 202.83 | 20.52 | 69.33 | 5.11 |
| 2016-09-30 | 192.42 | 19.12 | 67.37 | 5.12 |
| 2016-06-30 | 178.78 | 16.57 | 63.53 | 4.89 |
| 2016-03-31 | 168.24 | 12.53 | 60.22 | 4.49 |
| 2015-12-31 | 159.01 | 11.59 | 57.03 | 4.18 |
| 2015-09-30 | 147.68 | 9.24 | 53.41 | 3.62 |
| 2015-06-30 | 136.29 | 8.55 | 49.15 | 3.30 |
| 2015-03-31 | 122.66 | 6.94 | 44.92 | 3.21 |
| 2014-12-31 | 112.54 | 5.27 | 42.03 | 2.98 |
| 2014-09-30 | 103.18 | 5.86 | 39.35 | 2.89 |
| 2014-06-30 | 93.57 | 2.78 | 37.15 | 2.77 |
| 2014-03-31 | 83.33 | 1.11 | 34.90 | 2.53 |
| 2013-12-31 | 75.44 | 0.21 | 32.13 | 2.40 |
| 2013-09-30 | 69.52 | -3.45 | 29.39 | 2.35 |
| 2013-06-30 | 62.90 | -3.75 | 26.84 | 2.23 |
| 2013-03-31 | 53.53 | -5.07 | 23.33 | 2.18 |
| 2012-12-31 | 48.58 | -5.22 | 20.86 | 2.26 |
*GAAP earnings excluding extraordinary items.
Performance last year
We want to ensure a company is making the most of what it has available. This is
done by comparing the return (profit) to a company's available
funds,
assets
and
capital.
- Inogen has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
- Inogen used its assets more efficiently than the US Medical Equipment industry average last year based on Return on Assets.
- Inogen has improved its use of capital last year versus 3 years ago (Return on Capital Employed).
Past performance checks
We assess Inogen's performance over the past 5 years by checking for:- Has earnings increased in past 5 years? (1 check)
- Has the earnings growth in the last year exceeded that of the Medical Equipment industry? (1 check)
- Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
- Is the Return on Equity (ROE) higher than 20%? (1 check)
- Is the Return on Assets (ROA) above industry average? (1 check)
- Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
Inogen has a total score of 5/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Full details on the Past part of the Simply Wall St company analysis model.
Health
How is Inogen's financial health and their level of debt?
A company's financial position is much like your own financial position,
it includes everything you own
(assets)
and owe
(liabilities).The boxes below represent the relative size of what makes up Inogen's finances.
The net worth of a company is the difference between its assets and liabilities.
- Inogen is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
- Inogen's cash and other short term assets cover its long term commitments.
Balance sheet
Assets
Liabilities and shares
- Low level of unsold assets.
- Inogen has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t
bad,
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
All data from Inogen Company Filings, last reported 2 months ago.
| Date (Data in USD Millions) | Total Equity | Total Debt | Cash & Short Term Investments |
|---|---|---|---|
| 2018-12-31 | 310.42 | 0.00 | 240.35 |
| 2018-09-30 | 291.26 | 0.00 | 223.86 |
| 2018-06-30 | 266.91 | 0.00 | 208.41 |
| 2018-03-31 | 246.34 | 0.00 | 188.30 |
| 2017-12-31 | 227.04 | 0.00 | 173.94 |
| 2017-09-30 | 221.29 | 0.00 | 163.09 |
| 2017-06-30 | 207.78 | 0.00 | 144.21 |
| 2017-03-31 | 192.78 | 0.00 | 128.24 |
| 2016-12-31 | 182.09 | 0.00 | 113.88 |
| 2016-09-30 | 156.08 | 0.08 | 108.34 |
| 2016-06-30 | 147.50 | 0.16 | 98.12 |
| 2016-03-31 | 138.19 | 0.24 | 86.09 |
| 2015-12-31 | 134.02 | 0.32 | 82.90 |
| 2015-09-30 | 129.92 | 0.39 | 74.12 |
| 2015-06-30 | 127.92 | 0.47 | 66.06 |
| 2015-03-31 | 122.57 | 0.54 | 61.10 |
| 2014-12-31 | 118.15 | 0.61 | 56.84 |
| 2014-09-30 | 113.91 | 0.66 | 56.16 |
| 2014-06-30 | 110.81 | 13.41 | 69.05 |
| 2014-03-31 | 107.90 | 9.19 | 59.55 |
| 2013-12-31 | 56.56 | 10.65 | 13.52 |
| 2013-09-30 | 34.40 | 12.03 | 17.06 |
| 2013-06-30 | 32.95 | 9.00 | 14.17 |
| 2013-03-31 | 28.74 | 8.94 | 15.11 |
| 2012-12-31 | 28.74 | 8.94 | 15.11 |
- Inogen has no debt.
- Inogen has no debt compared to 5 years ago when it was 18.6%.
- Inogen has no debt, it does not need to be covered by operating cash flow.
- Inogen has no debt, therefore coverage of interest payments is not a concern.
Financial health checks
We assess Inogen's financial health by checking for:- Are short term assets greater than short term liabilities? (1 check)
- Are short term assets greater than long term liabilities? (1 check)
- Has the debt to equity ratio increased in the past 5 years? (1 check)
- Is the debt to equity ratio over 40%? (1 check)
- Is the debt covered by operating cash flow? (1 check)
- Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check) Inogen has a total score of 6/6, see the detailed checks below.
- Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
- Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
Full details on the Health part of the Simply Wall St company analysis model.
Dividends
What is Inogen's current dividend yield, its reliability and sustainability?
Dividends are regular cash payments to you from the company, similar to a
bank paying you interest on a savings account.
Annual Dividend Income
If you bought
$2,000 of
Inogen
shares you are expected to receive
$0
in your first year as a dividend.
Dividend Amount
- Unable to evaluate Inogen's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
- Unable to evaluate Inogen's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not
wildly increasing/decreasing each year. This graph shows you the historical rate
to count toward your assessment of the stock.We also check to see if the dividend has increased in the past 10 years.
| Data Point | Source | Value |
|---|---|---|
| Past Annualized Dividend Yield | S&P Global Market Data | See Below |
| Past Dividends per Share | Company Filings/ Annualized Dividend Payments | See Below |
| Future Dividends per Share Estimates | Average of up to 7 Analyst Estimates (S&P Global) | See Below |
| United States of America Medical Equipment Industry Average Dividend Yield | Market Cap Weighted Average of 24 Stocks | 1.3% |
| United States of America Market Average Dividend Yield | Market Cap Weighted Average of 2004 Stocks | 2.5% |
| United States of America Minimum Threshold Dividend Yield | 10th Percentile | 0.8% |
| United States of America Bottom 25% Dividend Yield | 25th Percentile | 1.4% |
| United States of America Top 25% Dividend Yield | 75th Percentile | 3.6% |
Industry and Market average data is calculated daily.
Note all dividend per share amounts are annualized and not quarterly or other period.
| Date (Data in $) | Dividend per Share (annual) | Avg. No. Analysts |
|---|---|---|
| 2023-12-31 | ||
| 2022-12-31 | ||
| 2021-12-31 | ||
| 2020-12-31 | ||
| 2019-12-31 |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Unable to perform a dividend volatility check as Inogen has not reported any payouts.
- Unable to verify if Inogen's dividend has been increasing as the company has not reported any payouts.
Income/ dividend checks
We assess Inogen's dividend by checking for:- Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
- Is current dividend yield above the bottom 25% of dividend payers? (1 check)
- Is current dividend yield above the top 25% of dividend payers? (1 check)
- Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
- If they have paid a dividend for 10 years has it increased in this time? (1 check)
- How sustainable is the dividend, can Inogen afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks) Inogen has a total score of 0/6, see the detailed checks below.
Full details on the Dividends part of the Simply Wall St company analysis model.
Management
CEO
| COMPENSATION | $2,848,366 |
| AGE | 53 |
| TENURE AS CEO | 2 years |
CEO Bio
Mr. Scott Wilkinson has been the Chief Executive Officer of Inogen, Inc. since March 1, 2017 and as its President since January 1, 2016. Mr. Wilkinson served as the Chief Operating Officer of Inogen, Inc. from January 1, 2016 to March 1, 2017. Mr. Wilkinson served as an Executive Vice President of Sales & Marketing at Inogen, Inc. since 2008 until December 31, 2015. Mr. Wilkinson served as Senior Vice President of Product Management at Inogen, Inc. Mr. Wilkinson has 20 years experience and a diverse background in Product Management, Operations and Research & Development. Mr. Wilkinson served as Group Product Manager for Oxygen Therapy at Invacare Corporation where he led the introduction of the HomeFill II Oxygen System. He has additional medical device management experience as a Product Line Director of Johnson & Johnson and a Product Manager of Kimberly-Clark Corporation in the Professional Health Care Sector. He has been Director of Inogen, Inc. since January 1, 2017. Mr. Wilkinson received a Bachelor’s degree in Chemical Engineering from the University of Akron and an MBA from University of Wisconsin, Oshkosh.
CEO Compensation
- Scott's compensation has increased by more than 20% in the past year.
- Scott's remuneration is about average for companies of similar size in United States of America.
Management Team Tenure
Average tenure and age of the Inogen management team in years:
- The tenure for the Inogen management team is about average.
Management Team
Scott Wilkinson
CEO, President & Director
$3M
53
2 yrs
Brenton Taylor
Executive Vice President of Engineering
$793K
37
18.2 yrs
Ali Bauerlein
Executive VP of Finance
$1M
37
18.2 yrs
Byron Myers
Executive Vice President of Sales & Marketing
$919K
39
2.2 yrs
Bart Sanford
Executive Vice President of Operations
52
0.5 yrs
Matt Bacso
Investor Relations & Corporate Development Manager
Board of Directors Tenure
Average tenure and age of the Inogen board of directors in years:
- The tenure for the Inogen board of directors is about average.
Board of Directors
Heath Lukatch
Chairman of the Board
$436K
51
11.2 yrs
Scott Wilkinson
CEO, President & Director
$3M
53
2.2 yrs
R. Greer
Independent Director
$329K
60
3.6 yrs
Loren McFarland
Independent Director
$388K
59
6.2 yrs
Heather Rider
Independent Director
$327K
58
4.6 yrs
Richard Casaburi
Member of Advisory Board
Jeffrey Kupperman
Member of Advisory Board
Paul Selecky
Member of Advisory Board
Neil MacIntyre
Member of Advisory Board
Robert Chatburn
Member of Advisory Board
Who owns this company?
Recent Insider Transactions
| Announced | Type | Name | Entity | Role | Start | End | Shares | Max Price ($) | Value ($) | |
|---|---|---|---|---|---|---|---|---|---|---|
Management checks
We assess Inogen's management by checking for:- Is the CEO's compensation unreasonable compared to market cap? (1 check)
- Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
- Is the average tenure of the management team less than 2 years? (1 check)
- Is the average tenure of the board of directors team less than 3 years? (1 check) Inogen has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.
Note: We use the top 6 management executives and board members in our calculations.
Note 2: Insider trading include any internal stakeholders and these transactions .
Full details on the Management part of the Simply Wall St company analysis model.
News
Simply Wall St News
Introducing Inogen (NASDAQ:INGN), The Stock That Soared 460% In The Last Five Years
(NASDAQ:INGN) shareholders have seen the share price descend 29% over the month. … The most important thing for savvy investors to consider is whether the underlying business can justify the share price gain. … One way to examine how market sentiment has changed over time is to look at the interaction between a company's share price and its earnings per share (EPS).
Simply Wall St - – Full articleWhat Should You Know About Inogen, Inc.'s (NASDAQ:INGN) Growth?
Inogen, Inc.'s (NASDAQ:INGN) released its most recent earnings update in December 2018, whicha … signalled
Simply Wall St - – Full articleHere's What Inogen, Inc.'s (NASDAQ:INGN) P/E Is Telling Us
This article is for investors who would like to improve their understanding of price to earnings ratios (P/E ratios). … Inogen has a price to earnings ratio of 71.19, based on the last twelve months. … How Do I Calculate A Price To Earnings Ratio
Simply Wall St - – Full articleA Closer Look At Inogen, Inc.'s (NASDAQ:INGN) Impressive ROE
With that in mind, this article will work through how we can use Return On Equity (ROE) to better understand a business. … Another way to think of that is that for every $1 worth of equity in the company, it was able to earn $0.14. … Return on Equity = Net Profit ÷ Shareholders' Equity
Simply Wall St - – Full articleInogen, Inc. (NASDAQ:INGN): Can Growth Justify Its January Share Price?
Let’s take a look at some key metrics to determine whether there's any value here for current and potential future investors. … Want to help shape the future of investing tools. … Investors in Inogen have been patiently waiting for the uptick in earnings.
Simply Wall St - – Full articleHas Inogen, Inc. (NASDAQ:INGN) Got Enough Cash?
Today we will look at INGN’s financial liquidity and debt levels, which are strong indicators for whether the company can weather economic downturns or fund strategic acquisitions for future growth. … Remember this is a very top-level look that focuses exclusively on financial health, so I recommend a deeper analysis. … Want to help shape the future of investing tools and platforms
Simply Wall St - – Full articleWhat Are Analysts Saying About Inogen, Inc.'s (NASDAQ:INGN) Growth?
(NASDAQ:INGN) released its earnings update. … with earnings expected to grow by 19% in the upcoming year … the higher past 5-year average growth rate of 48%
Simply Wall St - – Full articleAn Examination Of Inogen, Inc. (NASDAQ:INGN)
(NASDAQ:INGN) is a company with exceptional fundamental characteristics. … Upon building up an investment case for a stock, we should look at various aspects. … is a company with great financial health as well as a.
Simply Wall St - – Full articleWhy You Should Buy Inogen Inc (NASDAQ:INGN) In This Bear Market
High quality stocks such as Inogen Inc has fared well over time in a fickle stock market, which is why I want to bring it into light amongst all the chaos. … Below I take a look at three key features of what makes a robust defensive stock investment: its size, financial health and track record. … Inogen, Inc., a medical technology company, primarily develops, manufactures, and markets portable oxygen concentrators for patients, physicians and other clinicians, and third-party payors in the United States and internationally
Simply Wall St - – Full articleWhat Does Inogen Inc's (NASDAQ:INGN) P/E Ratio Tell You?
This article is written for those who want to get better at using price to earnings ratios (P/E ratios). … We'll look at Inogen Inc's (NASDAQ:INGN) P/E ratio and reflect on what it tells us about the company's share price. … Price to Earnings Ratio = Share Price ÷ Earnings per Share (EPS)
Simply Wall St - – Full articleCompany Info
Description
Inogen, Inc., a medical technology company, primarily develops, manufactures, and markets portable oxygen concentrators for patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The company offers Inogen One, a portable device that concentrate the air around the patient to provide a single source of supplemental oxygen; and Inogen At Home stationary oxygen concentrators, as well as related accessories. The company also rents its products directly to patients. Inogen, Inc. was founded in 2001 and is headquartered in Goleta, California.
Details
| Name: | Inogen, Inc. |
| INGN | |
| Exchange: | NasdaqGS |
| Founded: | 2001 |
| $2,096,629,558 | |
| 21,814,895 | |
| Website: | http://www.inogen.com |
| Address: |
Inogen, Inc. 326 Bollay Drive, Goleta, California, 93117, United States |
Listings
| Exchange Symbol | Ticker Symbol | Security | Exchange | Country | Currency | Listed on | |
|---|---|---|---|---|---|---|---|
| NasdaqGS | INGN | Common Stock | Nasdaq Global Select | US | USD | 14. Feb 2014 | |
| DB | 6IO | Common Stock | Deutsche Boerse AG | DE | EUR | 14. Feb 2014 |
Number of employees
Current staff
Industry
| Health Care Equipment | |
| Healthcare |
Company Analysis and Financial Data Status
| Area | Date (UTC time) |
|---|---|
| Company Analysis updated: | 2019/03/20 00:33 |
| End of day share price update: | 2019/03/19 00:00 |
| Last estimates confirmation: | 2019/02/27 |
| Last earnings filing: | 2019/02/26 |
| Last earnings reported: | 2018/12/31 |
| Last annual earnings reported: | 2018/12/31 |
All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
